Natera announced the commercial launch of Zenith Genomics, a whole‑genome sequencing assay that combines long‑read sequencing with methylation analysis to detect disease‑related epigenetic signatures. The product expands the company’s portfolio beyond its established cell‑free DNA and oncology testing and positions it to capture a larger share of the rare‑disease diagnostics market.
The launch is the result of a partnership with MyOme, Inc., whose technology provides the long‑read sequencing and methylation‑analysis capabilities that underpin Zenith Genomics. The assay’s dual‑analysis approach enables the detection of epigenetic signatures that traditional sequencing methods miss, and it is designed to resolve variants of uncertain significance and imprinting conditions that often stall rare‑disease diagnoses.
Rare diseases affect an estimated 30 million Americans annually, and patients typically endure diagnostic odysseys of 4–7 years. The cumulative economic burden in the U.S. was nearly $997 billion in 2019, with $449 billion in direct medical costs and $548 billion in indirect and non‑medical costs. By offering a more comprehensive genomic test, Zenith Genomics addresses a critical unmet need and could shorten the diagnostic journey for many families.
Natera’s Q4 2025 results provide a strong financial foundation for the launch. Revenue reached $665.5 million, a 39.8% year‑over‑year increase, and gross margin expanded to 66.9% from 62.9% in Q4 2024. The company guided 2026 revenue to $2.62 billion–$2.70 billion and gross margin to 63%–65%, reflecting confidence in continued growth and operational leverage. The new assay builds on this momentum and is expected to contribute to future revenue and margin expansion.
Management emphasized the strategic importance of the launch. "Rare disease patients and their families endure lengthy and costly diagnostic journeys that often delay care and elevate emotional and financial strain. By combining MyOme's innovation with Natera's nationwide presence and clinical expertise, Zenith has the potential to transform rare disease diagnostics and provide definitive answers to more families," said Meredith Reichert, senior vice president of commercial and general manager of rare disease at Natera. "Our mission at MyOme has always been to unlock the full potential of the genome to improve health outcomes. Partnering with Natera allows us to scale Zenith rapidly and responsibly, ensuring that advanced sequencing tools reach the patients who need them most," added Akash Kumar, chief medical officer at MyOme. "It is increasingly clear that the next frontier in addressing rare diseases involves probing genome function alongside sequence."
The competitive landscape reacted to the announcement. GeneDx, a competitor offering whole‑genome sequencing for rare diseases, saw its shares decline 4% following the launch, indicating market perception of a competitive threat. Natera’s unique combination of long‑read sequencing and methylation analysis differentiates Zenith Genomics from existing offerings and positions the company to capture a larger share of the rare‑disease diagnostics market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.